Powering Biopharma Breakthroughs from Preclinical to Commercial Manufacturing

By combining four advanced optical technologies, Prometheus Panta C streamlines developability assessments, process monitoring, and protein identity characterization - all while requiring minimal sample volume.

As regulatory pressures grow and timelines shrink, biopharma teams need data they can trust – fast. Controlled by software designed to meet 21 CFR Part 11 regulatory standards, Prometheus Panta C facilitates data integrity through distinct user access groups, while Active Directory integration provides centralized user authentication. Features such as electronic signatures, electronic records, and comprehensive audit trails further strengthen regulatory alignment.

“This pioneering system enables companies to precisely characterize and identify proteins from preclinical phase through to commercial manufacturing. Our vision is to make every disease treatable – and this is a step toward that future.”

Fully compatible with LIMS, automation platforms, and both low- and high-throughput workflows, Prometheus Panta C supports scalable, data-driven analysis. It delivers critical data in under two hours, accelerating decision-making, reducing risk, and helping bring biologics to market faster.